Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00806208 · ClinicalTrials.gov registry record · Phase 1
Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT00806208 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 34 participants.
The verdict
NCT00806208, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
A trial to assess safety of four doses of MEDI 507 combined with another drug for initial treatment of at least Grade II acute Graft-vs-Host Disease in recipients.
Interventions
- OTHER Placebo
- DRUG MEDI-507
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 1999-01 |
| Est. Completion | 2000-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00806208
The ClinicalTrials.gov registry entry for NCT00806208 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00806208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00806208 about?
NCT00806208 is a clinical study titled "Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)". A trial to assess safety of four doses of MEDI 507 combined with another drug for initial treatment of at least Grade II acute Graft-vs-Host Disease in recipients.
What is the current status of trial NCT00806208?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 1999-01. Estimated completion is 2000-03.
What interventions are being tested in trial NCT00806208?
The interventions under investigation include: Placebo (OTHER), MEDI-507 (DRUG).
Who is sponsoring clinical trial NCT00806208?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.